Skip to main content

What are the different types of buprenorphine/naloxone?

Medically reviewed by Judith Stewart, BPharm. Last updated on July 5, 2024.

What are the different brand names? What are the different dosage forms?

Official answer

by Drugs.com

Buprenorphine and naloxone is a combination medicine used for the maintenance treatment of opioid dependence in adults. It is available in sublingual film and sublingual tablet dosage forms under the brand names Suboxone, Zubsolv, Bunavail (discontinued), and Cassipa (discontinued).

Buprenorphine is a long-acting, partial opioid agonist that is used in people who are addicted to shorter-acting opioid drugs (such as heroin, hydrocodone, oxycodone, morphine and fentanyl) to reduce the withdrawal symptoms and cravings associated with opioid dependence.

Naloxone is an opioid antagonist that works to discourage people who are dependent on intravenous (IV) opioids from injecting the buprenorphine/naloxone combination.

Buprenorphine/naloxone is used as part of a complete treatment program that also includes counseling and behavioral therapy.

Because the buprenorphine/naloxone combination contains buprenorphine (which belongs to the class of drugs called narcotic analgesics) it is listed under Schedule III of the Controlled Substances Act (CSA) due to its potential for abuse.

Buprenorphine/Naloxone Formulations Available in the United States

Brand Dosage Form Administration Use Company Approved Generic Available
Cassipa
(discontinued)
sublingual film once daily opioid dependence Teva Pharmaceuticals USA, Inc. 2018 No
Bunavail
(discontinued)
buccal film once daily opioid dependence BioDelivery Sciences International, Inc. 2014 No
Zubsolv sublingual tablets once daily opioid dependence Orexo US, Inc. 2013 No
Suboxone sublingual film once daily opioid dependence Indivior Inc. 2010 Yes
Suboxone
(discontinued)
sublingual tablets once daily opioid dependence Indivior Inc. 2002 Yes

Related questions

Read next

Is buprenorphine an opiate / narcotic?

Buprenorphine is classified as an opioid partial agonist and is considered a narcotic, but It activates the mu-opioid receptor to a lesser extent than the full opioid agonists (for example: oxycodone, methadone or morphine). It's used at higher doses for opioid use disorder (opioid dependence) while generally at lower doses to treat moderate to severe pain. Continue reading

What is the difference between Sublocade and Brixadi?

Sublocade and Brixadi are both subcutaneous long-acting buprenorphine injections that may be used for the maintenance treatment of opioid misuse disorder in adults. Sublocade was approved on November 30, 2017, and Brixadi was approved on May 23, 2023. Sublocade is administered once a month, with a minimum of 26 days between doses. If extended travel is deemed necessary, a single 300mg injection may be given to cover 2 months. Brixadi is given once a week or once a month. Continue reading

How long do you take buprenorphine for?

There is no one-size-fits-all treatment duration for patients taking buprenorphine. There are many factors involved in determining the length of treatment when administering buprenorphine. Continue reading

Related medical questions

Related support groups